Table 1.

Clinical characteristics at time of presentation and follow-up data of renal disease in patients with anti-LRP2 nephropathy

Pt	Age	Sex	Race	Cr, mg/d	Prot, g	Hem	ANA	dsDNA	ANCA	C3	C4	S alb, g/dl	Past medical history	F/U, mo	Treatment	Outcome
1	68	M	H	8.8	NAa	NAa	—	—	—	Nml	Nml	2	Recent B cereus infection	8	Prednisone	Renal replacement
2	78	M	W	3	3.3	+	—	NP	BL+	Nml	Nml	4	DM and HTN	12	Prednisone, cytoxan	Serum Cr: 2 mg/dl; known serologic remission
3	76	M	W	1.7	0.5	+	1:320	—	NP	Nml	Nml	3.6	COPD	4	Rituximab	Renal replacement/deceased
4	69	F	W	2.7	1.5	+	—	—	—	Nml	Nml	3.5	DM	15	Prednisone	Serum Cr: 4.2 mg/dl
5	72	M	W	5	0.8	+	1:40	—	—	Nml	Nml	4.1	DM	3	Prednisone	Renal replacement/deceased
6	70	M	W	2.2	1.1	+	1:640	Weak +	—	Nml	Nml	4	HTN, gout, nephrolithiasis	10	None	Serum Cr: 2.3 mg/dl
7	73	M	W	15.2	1.3	+	—	—	—	Nml	Nml	?	CAD, DM, HTN	48	Prednisone	Kidney transplant with recurrence
8	66	F	W	6.7	0.9	+	—	—	—	Dec	Nml	4	DM, HTN	3	None	Serum Cr: 2.5 mg/d
9	77	F	W	2.3	0.6	+	—	—	—	Nml	Nml	3.7	Sarcoidosis	6	None	Serum Cr: 2.1 mg/dl
10	80	M	W	14.7	NAa	NAa	—	—	—	Nml	Nml	3.3	HTN	1.5	Prednisone	Renal replacement

Pt, patient; Cr, creatinine; Prot, 24-hour proteinuria; Hem, hematuria; ANA, antinuclear antibody; dsDNA, antidouble-stranded DNA; C4, serum complement C4; S alb, serum albumin; F/U, follow-up; M, man; H, Hispanic; NA, not applicable; —, negative; Nml, normal; W, white; NP, not performed; BL, borderline; DM, diabetes mellitus; HTN, hypertension; COPD, chronic obstructive pulmonary disease; F, woman; ?, unknown; CAD, coronary artery disease; Dec, decreased.

^aPatient was anuric on presentation.